IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will compare the immune system response to booster vaccines for tetanus/diphtheria and hepatitis B in healthy volunteers with that of patients who have had a blood transplant. (A blood transplant is an infusion of donated stem cells-i.e., cells that mature into white blood cells, red blood cells and platelets). The study will also look at how age of the blood cell donor and recipient, the type of blood transplant, the amount of certain types of white cells in donor blood, and other variables may influence the vaccine response among the transplant patients.
This study includes normal volunteers and patients who have had a blood transplant. Healthy volunteers between the ages of 18 and 60 who have previously been vaccinated with the hepatitis B or tetanus/diphtheria vaccine and have not had hepatitis B may be eligible for this study. Patients enrolled in a blood cell transplant study at NIH who are between 5 and 60 years old, have been vaccinated against tetanus/diphtheria, and have not had hepatitis B may be eligible. Candidates will be screened with a medical history and blood tests.
Those enrolled in the study will have about 2 tablespoons of blood drawn before vaccination with a standard tetanus/diphtheria booster shot. Volunteers who have previously been vaccinated with the hepatitis B vaccine and all blood transplant patients will also receive a hepatitis B vaccination. Participants will have blood drawn (from 1 to 5 tablespoons) up to once a week after vaccination for no more than 8 weeks to evaluate the immune response to vaccination.
| Condition |
|---|
| Active Immunity Healthy Stem Cell Transplantation |
| Study Type: | Observational |
| Official Title: | Evaluation of Hepatitis B Surface Antigen-Specific and Tetanus Toxoid-Specific Lymphocytes |
| Estimated Enrollment: | 55 |
| Study Start Date: | June 2000 |
| Estimated Study Completion Date: | May 2002 |
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
HEALTHY VOLUNTEERS:
Male or female subjects who are at least 18 years of age, but no older than 60 years of age.
Received complete hepatitis B and/or tetanus/diphtheria vaccination series.
If female, have a negative urine or serum pregnancy test within two weeks prior to entry into this study, and agree to avoid pregnancy during entire participation through the use of effective birth control or abstinence.
Volunteers reporting good general health and denying any illness that can adversely affect an immune response to a vaccine.
No history of a serious adverse event associated with any previous vaccination.
Not participating in another experimental vaccine study.
Serum hemoglobin greater than or equal to 11 g/dL.
No history of hepatitis B.
Must not have received a tetanus/diphtheria or hepatitis B booster in the last 6 months.
HSCT VOLUNTEERS:
Male or female subjects who are at least 5 years of age, but no older than 60 years of age.
Be enrolled in a HSCT protocol at NIH.
Be greater than or equal to 3 months post-HSCT.
Received tetanus/diphtheria vaccination series.
If female, have a negative urine or serum pregnancy test within two weeks prior to entry into this study, and agree to avoid pregnancy during entire participation through the use of effective birth control or abstinence.
No history of a serious adverse event associated with any previous vaccination.
Not participating in another experimental vaccine study.
Serum hemoglobin greater than or equal to 9 g/dL.
No history of hepatitis B.
Not receiving any more than replacement glucocorticoid therapy.
Not receiving any dose of cyclosporine.
No acute graft-versus-host disease grade II or higher, at time of consideration for study.
No chronic graft-versus-host disease more involved than localized skin lesions and/or liver dysfunction, at time of consideration for study.
Must not have received a tetanus/diphtheria or hepatitis B booster in the last 6 months.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00005907
| United States, Maryland | |
| National Institute of Allergy and Infectious Diseases (NIAID) | |
| Bethesda, Maryland, United States, 20892 | |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00005907 History of Changes |
| Other Study ID Numbers: |
000144 00-I-0144 |
| Study First Received: | June 9, 2000 |
| Last Updated: | March 3, 2008 |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
B Cell Reconstitution T Cell Transplant Vaccine |
ClinicalTrials.gov processed this record on August 23, 2017